Alpha Adhesives & Sealants Ltd

alpha-adhesives.co.uk

Established in 1987 Alpha has become a worldwide supplier of quality Adhesives, Sealants & coatings that are manufactured at its UK base in Stourport on Severn, Worcestershire. In 2004 Alpha acquired the Industrial Adhesives Division of DUNLOP who's origins date back to the early 1900's and are synonymous with brand names such as thixofix. Alpha have the commitment and ability to develop and manufacture products for particular specialist applications and prides itself with offering customers a working partnership in order to achieve the best possible results together.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

news image

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More

ELI LILLY, SITRYX SIGN POTENTIAL $880M DEAL TO DEVELOP IMMUNOMETABOLIC MEDICINES

Pharmaceutical Business review - | April 01, 2020

news image

Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines. Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The new targets may help develop potential new medicines for autoimmune diseases. Lilly immunology vice president Dr Ajay Nirula said: “As Lilly seeks to develop new and unique medicines for people s...

Read More

PHARMACY MARKET

EMA STARTS ROLLING REVIEW OF CUREVAC’S COVID-19 VACCINE (CVNCOV)

CureVac, EMA | February 18, 2021

news image

The European Medicines Agency (EMA's) Committee for Human Medicinal Products (CHMP) has begun a moving audit of CureVac AG's COVID-19 antibodies, CVnCoV. The survey was started on the grounds that starter research facility contemplates and early clinical preliminary outcomes recommend the immunization triggers the creation of antibodies and insusceptible cells that target SARS-CoV-2, the infection that causes COVID‑19. The survey will successively audit info...

Read More

BUSINESS INSIGHTS, PHARMA TECH

USP INTRODUCES ANALYTICAL R&D TO OPTIMIZE CONTINUOUS MANUFACTURING TECHNOLOGIES

US Pharmacopeia | January 04, 2023

news image

The United States Pharmacopeia (USP) has announced the launch of the USP Advanced Manufacturing Technology Lab in Richmond, Virginia, as a part of its launch of a suite of R&D analytical solutions. These analytical lab services will aid drug manufacturers in adopting advanced manufacturing technologies, such as pharmaceutical continuous manufacturing (PCM), to increase geographic diversity in pharmaceutical manufacturing and support medicine supply chain resilience. The new R&...

Read More
news image

PHARMA TECH

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More
news image

ELI LILLY, SITRYX SIGN POTENTIAL $880M DEAL TO DEVELOP IMMUNOMETABOLIC MEDICINES

Pharmaceutical Business review - | April 01, 2020

Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines. Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The new targets may help develop potential new medicines for autoimmune diseases. Lilly immunology vice president Dr Ajay Nirula said: “As Lilly seeks to develop new and unique medicines for people s...

Read More
news image

PHARMACY MARKET

EMA STARTS ROLLING REVIEW OF CUREVAC’S COVID-19 VACCINE (CVNCOV)

CureVac, EMA | February 18, 2021

The European Medicines Agency (EMA's) Committee for Human Medicinal Products (CHMP) has begun a moving audit of CureVac AG's COVID-19 antibodies, CVnCoV. The survey was started on the grounds that starter research facility contemplates and early clinical preliminary outcomes recommend the immunization triggers the creation of antibodies and insusceptible cells that target SARS-CoV-2, the infection that causes COVID‑19. The survey will successively audit info...

Read More
news image

BUSINESS INSIGHTS, PHARMA TECH

USP INTRODUCES ANALYTICAL R&D TO OPTIMIZE CONTINUOUS MANUFACTURING TECHNOLOGIES

US Pharmacopeia | January 04, 2023

The United States Pharmacopeia (USP) has announced the launch of the USP Advanced Manufacturing Technology Lab in Richmond, Virginia, as a part of its launch of a suite of R&D analytical solutions. These analytical lab services will aid drug manufacturers in adopting advanced manufacturing technologies, such as pharmaceutical continuous manufacturing (PCM), to increase geographic diversity in pharmaceutical manufacturing and support medicine supply chain resilience. The new R&...

Read More